Breaking News

Zillow Buys Trulia for $3.5 Billion in Stock
Tweet TWEET

Helsinn and DARA Announce U.S. Launch of Gelclair®, an FDA-Cleared Oral Gel for the Treatment of Oral Mucositis

 Helsinn and DARA Announce U.S. Launch of Gelclair®, an FDA-Cleared Oral Gel
                     for the Treatment of Oral Mucositis

  PR Newswire

  LUGANO, Switzerland and RALEIGH, North Carolina, April 22, 2013

LUGANO, Switzerland and RALEIGH, North Carolina, April 22, 2013 /PRNewswire/
--

The Swiss pharmaceutical Helsinn Group, a leading player in the cancer
supportive care arena, announced today that DARA BioSciences, Inc., a U.S.
specialty pharmaceutical company focused on oncology and oncology supportive
care products, has launched Gelclair ^® into the U.S. market. Gelclair ^® is
manufactured by the Helsinn Group and is an FDA-cleared product indicated for
the treatment of oral mucositis.

Oral mucositis is a painful inflammation and ulceration of the surface of the
mouth and throat, which can result from a variety of cancer treatments.
Gelclair ^® provides oral mucositis patients rapid and effective relief of
pain. Oral mucositis is common in cancer patients undergoing chemotherapy or
radiation therapy and occurs when the protective oral mucosa is denuded,
potentially resulting in pain, infection, weight loss, decreased quality of
life, treatment delay and increased economic costs.

Helsinn Group Chief Executive Officer, Riccardo Braglia, said, "We are pleased
that DARA is launching Gelclair ^® in the United States, and importantly, that
U.S. patients will again be able to benefit from this treatment. We believe
this is an important milestone in building the long-term relationship between
our companies. It will also add the most important market worldwide to the
other 30 where Gelclair ^® is already marketed in Europe, Latin America and
Asia."

David J. Drutz, MD, DARA's Chief Executive Officer and Chief Medical Officer,
stated, "We are thrilled to be launching Gelclair ^® , our third product into
the U.S. market, having recently introduced Soltamox ^® (tamoxifen citrate)
oral solution, the first and only liquid version of tamoxifen citrate. We
believe this underpins our mission of becoming a leader in the oncology and
oncology supportive care market and exemplifies our commitment to executing
against our corporate plan."

About Helsinn Group

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano,
Switzerland, and operating subsidiaries in Ireland, the United States and
China. Helsinn's business model is focused on the licensing of
pharmaceuticals, medical devices and nutritional supplement products in
therapeutic niche areas. Helsinn is an important player in cancer supportive
care. Helsinn Group in-licenses early-to-late stage new chemical entities,
completes their development through the performance of pre-clinical/clinical
studies and Chemistry, Manufacturing, and Control (CMC) development, and files
and attains their market approvals worldwide. Helsinn's products are
out-licensed to its network of local marketing and commercial partners,
selected for their deep in-market knowledge and know-how whom Helsinn assists
and supports by providing a full range of product and scientific management
services, including commercial, regulatory, financial, legal, and medical
marketing advice. The active pharmaceutical ingredients and the finished
products are manufactured according to the highest quality, safety, and
environmental standards at Helsinn's GMP facilities in Switzerland and Ireland
and supplied worldwide to its customers.

Further information on Helsinn Group is available at http://www.helsinn.com

About DARA BioSciences, Inc.

DARA is a specialty pharmaceutical company focused on the development and
commercialization of oncology treatment and supportive care products.

For more information please visit our web site at: http://www.darabio.com

Safe Harbor  All statements in this news release that are not historical are
forward-looking statements within the meaning of the Securities Exchange Act
of 1934, as amended. Such forward-looking statements are subject to factors
that could cause actual results to differ materially for DARA from those
projected. Those factors include risks and uncertainties relating to DARA's
ability to timely commercialize and generate revenues or profits from Bionect
® , Soltamox®, Gelclair® or other products given that DARA only recently hired
its initial sales force and DARA's lack of history as a revenue-generating
company, FDA and other regulatory risks relating to DARA's ability to market
Bionect, Soltamox, Gelclair or other products in the U.S. or elsewhere, DARA's
ability to develop and bring new products to market as anticipated, DARA's
current cash position and its need to raise additional capital in order to be
able to continue to fund its operations, the current regulatory environment in
which DARA develops and sells its products, the market acceptance of those
products, dependence on partners, successful performance under collaborative
and other commercial agreements, competition, the strength of DARA's
intellectual property and the intellectual property of others, the potential
delisting of DARA's common stock from the NASDAQ Capital Market, risks and
uncertainties relating to DARA's ability to successfully integrate Oncogenerix
and other risk factors identified in the documents DARA has filed, or will
file, with the Securities and Exchange Commission ("SEC"). Copies of DARA's
filings with the SEC may be obtained from the SEC Internet site at
http://www.sec.gov . DARA expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in DARA's expectations with regard
thereto or any change in events, conditions, or circumstances on which any
such statements are based. DARA BioSciences and the DARA logo are trademarks
of DARA BioSciences, Inc.

For Helsinn Group Paola Bonvicini Head of Communication & Press Office Tel.:
+41-91-985-21-21 E-Mail: Info-hhc@helsinn.com

For DARA BioSciences, Inc.: Jenene Thomas Investor Relations + Corporate
Communications Advisor Tel.: +1-908-938-1475 E-Mail: jthomas@darabio.com